Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P47989
UPID:
XDH_HUMAN
Alternative names:
-
Alternative UPACC:
P47989; Q16681; Q16712; Q4PJ16
Background:
Xanthine dehydrogenase/oxidase plays a pivotal role in purine degradation, catalyzing the transformation of hypoxanthine to xanthine and further to uric acid, while also contributing to reactive oxygen species generation. Its activity extends to the oxidation of aldehydes, albeit at a lower efficiency.
Therapeutic significance:
Xanthinuria 1, a disorder marked by excessive urinary excretion of xanthine and reduced serum uric acid levels, is directly linked to mutations affecting this enzyme. Understanding its mechanism could pave the way for innovative treatments for this and potentially other related metabolic disorders.